CLVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Clarivate PLC (CLVT) is not a strong buy for a beginner investor with a long-term strategy at this time. Despite a recent surge in price and hedge fund interest, the company's financial performance, analyst sentiment, and strategic challenges suggest caution. Holding the stock may be a better approach until clearer positive trends emerge.
The stock shows a positive MACD histogram and RSI at 72.973, indicating a bullish momentum. However, moving averages are converging, and the stock is trading near resistance levels (R1: 2.358, R2: 2.556), which could limit further upside in the short term.
Hedge funds have significantly increased their buying activity by 182.82% over the last quarter. The company recently exceeded Q4 earnings and sales expectations, with a 31.4% surge in stock price following the announcement.
Analysts have consistently lowered price targets, with some downgrading the stock due to slow revenue growth, competition, and strategic challenges. The company's financial performance in Q4 2025 showed a significant decline in revenue, net income, and EPS. Additionally, the planned sale of its Life Sciences and Healthcare unit introduces deal risk.
In Q4 2025, revenue dropped by 6.94% YoY to $617 million, net income fell by 101.62% YoY to $3.1 million, and EPS declined by 100% YoY to $0. Gross margin also declined to 36.16%, down 3.83% YoY.
Analysts have a mixed to negative sentiment on the stock. Recent ratings include a lowered price target from Stifel ($6 from $7, Buy), Barclays ($2.40 from $4, Underweight), and Goldman Sachs ($3.10 from $3.60, Neutral). Analysts cite slow revenue growth, competition, and strategic challenges as concerns.
